XMax Inc. announced preliminary Q3 2026 results showing net sales of $6.42 million, down from $9.76 million in Q3 2025, but improved gross margin to 13.9%. The company expects a net loss of $12.10-$13.10 million due to non-cash losses. For the first nine months, sales fell to $10.94 million from $14.95 million, with a net income forecast of $19.50-$20.50 million driven by non-cash gains. CEO Andy Lu highlighted progress in AI business development, including partnerships and a $100 million revenue deal over five years. The board approved a $30 million share repurchase program, signaling confidence in long-term strategy. Final audited results will be released by November 16, 2026.
XMax Inc. announced preliminary Q3 2026 financial results, including a net sales decline to $6.42 million and an improved gross margin of 13.9%. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Nov 04, 2026 04:22 WIB: of 134 priced US stocks, 49 rose and 82 fell. Notable movers include DHI at USD 144.85 (-5.28%), LEN at USD 86.27 (-5.22%) with 100% buy order activity, and UAA at USD 5.25 (+5.21%) with a typical hold time of 100 days.
Vencora has acquired CT InsureTech, a leading insurance technology provider with offices in London, Buenos Aires, and Mexico City. This acquisition strengthens Vencora's insurance technology offerings and expands its presence in Latin America and Eur...
Vencora has acquired CT InsureTech, a leading provider of insurance technology and services with offices in London, Buenos Aires, and Mexico City. This acquisition expands Vencora's portfolio and presence in Latin America and the UK, strengthening it...
MediWound Ltd. announced a $15 million bought deal offering of 1.2 million ordinary shares at $12.50 each, led by H.C. Wainwright & Co. The offering is expected to close around November 5, 2026, with an option for the underwriter to purchase an addit...
Kadant Inc. announced strong Q3 2026 results with revenue up 15% to $313 million and net income rising 27% to $35 million, driven by 22% bookings growth and operational excellence. Adjusted EPS reached a record $3.64, and operating cash flow increase...
Vext Science reported a 17.6% increase in third-quarter revenue to $14.9 million, driven by a 37% year-over-year rise in Ohio sales, which reached $10.9 million. The company’s operating cash flow doubled from the previous quarter to $2.4 million, hel...
